Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective study to evaluate the safety and efficacy of Amifostine in preventing chemoradiotherapy-related Esophagitis in Small cell lung cancer patients

Trial Profile

A Retrospective study to evaluate the safety and efficacy of Amifostine in preventing chemoradiotherapy-related Esophagitis in Small cell lung cancer patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Amifostine (Primary)
  • Indications Radiation injuries
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2018 New trial record
    • 27 Sep 2018 Results presented in the Cumberland Pharmaceuticals media release.
    • 27 Sep 2018 According to a Cumberland Pharmaceuticals media release, the principal investigator of the trial is Ariel E Pollock M.D, Icahn School of Medicine at Mt. Sinai, New York.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top